The researchers discovered the medicine, CNI-14493, can transform amyloid into a form that doesn't aggregate to form plaques in the brain and also neutralizes the toxicity of the amyloid.
In his latest work, al-Abed was looking for a way to target the amyloid plaques that clump together between neurons in the brains of people with Alzheimer's disease.
Al-Abed, along with Michael Bacher and Richard Dodel of Marburg University in Germany, found the amyloid burden in the brain was reduced by 70 percent to 85 percent in areas hard hit in Alzheimer's patients -- the cortex and the hippocampus.
